Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement

ENANTA PHARMACEUTICALS INC

2022-Q3 EPS reported -$4.64 revenue$65,843,000

Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.
Cash, equivalents and marketable securities $292.7M; expects sufficient for two years.
Filed patent infringement suit against Pfizer over Paxlovid; seeks damages, not injunction; patent awarded June 2022.
EDP-235 Phase 1 data positive; Phase 2 study planned Q4 2022; RSV programs include new Phase 2 studies for EDP-938 and EDP-323.
Appointed Scott T. Rottinghaus as SVP and Chief Medical Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.